The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions

被引:100
|
作者
Cong, Mian-er [1 ]
Heneine, Walid [1 ]
Garcia-Lerma, J. Gerardo [1 ]
机构
[1] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA
关键词
D O I
10.1128/JVI.02712-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
It is generally accepted that the fitness cost of resistance mutations plays a role in the persistence of transmitted drug-resistant human immunodeficiency virus type I and that mutations that confer a high fitness cost are less able to persist in the absence of drug pressure. Here, we show that the fitness cost of reverse transcriptase (RT) mutations can vary within a 72-fold range. We also demonstrate that the fitness cost of M184V and K70R can be decreased or enhanced by other resistance mutations such as D67N and K219Q. We conclude that the persistence of transmitted RT mutants might range widely on the basis of fitness and that the modulation of fitness cost by mutational interactions will be a critical determinant of persistence.
引用
收藏
页码:3037 / 3041
页数:5
相关论文
共 50 条
  • [1] Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update
    Shafer, Robert W.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 216 : S843 - S846
  • [2] INTERACTIONS BETWEEN DRUG-RESISTANCE MUTATIONS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE
    LARDER, BA
    [J]. JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 951 - 957
  • [3] Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug
    Borman, AM
    Paulous, S
    Clavel, F
    [J]. JOURNAL OF GENERAL VIROLOGY, 1996, 77 : 419 - 426
  • [4] Fitness cost of drug resistance mutations is relative and is modulated by other resistance mutations:: implications for persistance of transmitted resistance
    Cong, M
    Bennett, DE
    Heneine, W
    García-Lerma, JG
    [J]. ANTIVIRAL THERAPY, 2005, 10 : S169 - S169
  • [5] Fitness cost of drug resistance mutations is relative and is modulated by other resistance mutations:: implications for persistance of transmitted resistance
    Cong, M
    Bennett, DE
    Heneine, W
    García-Lerma, JG
    [J]. ANTIVIRAL THERAPY, 2005, 10 (04) : S169 - S169
  • [6] Human immunodeficiency virus type 1 seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa
    Caron, Melanie
    Makuwa, Maria
    Souquiere, Sandrine
    Descamps, Diane
    Brun-Vezinet, Francoise
    Kazanji, Mirdad
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2008, 24 (09) : 1225 - 1228
  • [7] Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
    Maeda, Y
    Venzon, DJ
    Mitsuya, H
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05): : 1207 - 1213
  • [8] Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations
    Muzammil, S.
    Armstrong, A. A.
    Kang, L. W.
    Jakalian, A.
    Bonneau, P. R.
    Schmelmer, V.
    Amzel, L. M.
    Freire, E.
    [J]. JOURNAL OF VIROLOGY, 2007, 81 (10) : 5144 - 5154
  • [9] Human immunodeficiency virus type 1 infection in Oman: Antiretroviral therapy and frequencies of drug resistance mutations
    Al Dhahry, SHS
    Scrimgeour, EM
    Al Suwaid, AR
    Al Lawati, MRMY
    El Khatim, HS
    Al Kobaisi, MF
    Merigan, TC
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2004, 20 (11) : 1166 - 1172
  • [10] Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1
    Martinez-Picado, J
    Prado, JG
    Fry, EE
    Pfafferott, K
    Leslie, A
    Chetty, S
    Thobakgale, C
    Honeyborne, I
    Crawford, H
    Matthews, P
    Pillay, T
    Rousseau, C
    Mullins, JI
    Brander, C
    Walker, BD
    Stuart, DI
    Kiepiela, P
    Goulder, P
    [J]. JOURNAL OF VIROLOGY, 2006, 80 (07) : 3617 - 3623